stockrowResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
- Revenue
- +5.93%
- EPS
- +23.1%
- Free cash flow
- −9.79%
- Total debt
- −38.9%
Quarter to September 2026, against a year earlier
Follow RMD
Alert me
ResMed Inc. (RMD) Revenue
ResMed Inc.'s revenue for fiscal 2026 was $5.7B, up 9.85% from $5.1B in fiscal 2025. Over the twelve months to 30 September 2026 it was $5.7B. Over the past ten years it has ranged from $1.7B (fiscal 2015) to $5.7B (fiscal 2026) — the current reading is the highest in ten years. Revenue has risen for 11 consecutive fiscal years. ResMed Inc. ranks 8th of 47 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $5.7B | 9.85% |
| FY2025 | $5.1B | 9.84% |
| FY2024 | $4.7B | 10.95% |
| FY2023 | $4.2B | 18.02% |
| FY2022 | $3.6B | 11.93% |
| FY2021 | $3.2B | 8.11% |
| FY2020 | $3.0B | 13.44% |
| FY2019 | $2.6B | 11.38% |
| FY2018 | $2.3B | 13.23% |
| FY2017 | $2.1B | 12.40% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.4B | (3.34%) |
| Jun 2026 | $1.5B | 2.25% |
| Mar 2026 | $1.4B | 0.60% |
| Dec 2025 | $1.4B | 6.53% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDLN Medline Inc. compare | $30.7B |
| BDX Becton, Dickinson and Company compare | $20.8B |
| BAX Baxter International Inc. compare | $11.6B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation compare | $8.2B |
| RMD ResMed Inc. | $5.7B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| ALGN Align Technology, Inc. compare | $4.2B |
| WST West Pharmaceutical Services, Inc. compare | $3.4B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RMD
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement